Borregaard
Borregaard’s operating revenues increased to NOK 1,338 million (NOK 1,234 million)¹ in the 4th quarter of 2020. EBITDA² increased to NOK 263 million (NOK 183 million). All business areas improved their result compared with the corresponding quarter in 2019. The total net currency impact on EBITDA was slightly negative compared with the 4th quarter of 2019.
In BioSolutions, EBITDA increased due to improved product mix for biopolymers and lower operating expenses. BioMaterials had lower wood and energy costs and high deliveries compared with the weak result in the 4th quarter of 2019, which was impacted by operational incidents at the Sarpsborg site. A favourable product mix for pharma intermediates and higher sales volume for bioethanol were the main reasons for an improved result in Fine Chemicals.
Other income and expenses were NOK -20 million (NOK -11 million) in the 4th quarter due to environmental accruals for preventive measures related to former operations at the Sarpsborg site.
Profit before tax was NOK 119 million (NOK 30 million). Earnings per share were NOK 1.21 (NOK 0.38).
Full year 2020
Operating revenues in 2020 reached NOK 5,328 million (NOK 5,063 million). EBITDA increased to an all-time high of NOK 1,132 million (NOK 1,007 million). Profit before tax was NOK 496 million (NOK 467 million). Earnings per share were NOK 4.36 (NOK 4.17).
- We are pleased with the Group’s strong performance in 2020 and the way our organisation has handled a challenging coronavirus situation with significant disruptions for our operations, says President and CEO Per A. Sørlie.
Contacts:
Director Investor Relations, Jørn Syvertsen, +47 958 36 335
Director Communication, Tone Horvei Bredal, +47 924 67 711
1. Figures in parentheses are for the corresponding period in the preceding year
2. Operating profit before depreciation, amortisation and other income and expenses
This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
Attachments
- 4th quarter 2020 presentation
- 4th quarter 2020 report
- Quarterly and accounting figures 4th quarter 2020
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Zealand Pharma18.7.2025 18:30:00 CEST | Press release
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
SpringWorks Therapeutics, Inc.18.7.2025 17:30:40 CEST | Press release
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Photocat A/S18.7.2025 17:00:00 CEST | Press release
PHOTOCAT has today applied for a transfer of its trading venue from Nasdaq First North Growth Market to Spotlight Stock Market.
Golden Ocean Group Limited18.7.2025 16:30:00 CEST | Press release
GOGL – Notice of Special General Meeting
Kapitalforeningen SDG Invest18.7.2025 16:06:31 CEST | Pressemeddelelse
Kapitalforeningen SDG Invest - Opdateret prospekt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom